Licensing status

Publication and contact information


Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 (PREX1) levels predict response to phosphoinositide 3-kinase (PI3K) inhibition

In vitro studies suggest PREX1 expression in breast cancer could help predict sensitivity to PI3K inhibitors. Mutations that affect the PI3K pathway can increase sensitivity to PI3K inhibitors, but response is still inconsistent. In breast cancer cells with disruptions in the PI3K pathway, shRNA targeting PREX1 prevented decreased PI3K inhibition-induced apoptosis compared with a nontargeted shRNA control. In a panel of breast cancer cells with disruptions in the PI3K pathway, low PREX1 expression correlated with decreased response to PI3K inhibition. Next steps could include validating the biomarker in additional samples.

SciBX 7(2); doi:10.1038/scibx.2014.74
Published online Jan. 16, 2014

Patent and licensing status unavailable

Ebi, H. et al. Proc. Natl. Acad. Sci. USA; published online Dec. 10, 2013;
Contact: Jeffrey A. Engelman, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Mass.